BOVINE PARAINFLUENZA 3 VIRUS AS A NOVEL VACCINE VECTOR

牛副流感 3 病毒作为新型疫苗载体

基本信息

批准号：
6017911
负责人：
AURELIA A HALLER
金额：
$ 9.98万
依托单位：
MEDIMMUNE VACCINES, INC.
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
起止时间：
1999-08-15 至 2000-02-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6017911
关键词：
Paramyxovirus biotechnology genetic manipulation hamsters laboratory mouse parainfluenza virus type 1 parainfluenza virus type 2 respiratory syncytial virus technology /technique development transfection /expression vector vaccine development vector vaccine virus protein

项目摘要

Bovine parainfluenza type 3 virus (bPIV3) was shown in clinical trials to be safe when administered to small infants and children, and attenuated, causing no lower respiratory disease in children. bPIV3 was genetically stable after replication in children. These three characteristics provide the basis for the use of bPIV3 as an effective vector vehicle to deliver foreign antigens. Recently, an infectious cDNA of bPIV3 was engineered at Aviron that permits the isolation of recombinant viruses by reverse genetics. This Phase I SBIR proposal will demonstrate the feasibility of this approach by introducing the surface glycoproteins of human parainfluenza virus types l, 2 and 3 (hPIV1, 2, 3) and human respiratory syncytial virus (hRSV) (subgroups A and B) into the genetic genome of bPIV3. Both, hPIV and hRSV. are the causes of upper and lower respiratory disease in infants, children, and immunocompromised or elderly adults, resulting not only in significant numbers of hospitalizations but also in morbidity. No vaccine is currently available for either PIV or RSV associated disease and subunit approaches have so far failed. A Phase II SBIR grant will be used to complete preclinical testing in a subhuman primate model and to initiate human clinical trials. PROPOSED COMMERCIAL APPLICATIONS: The ultimate product of these studies are live attenuated human parainfluenza virus (types l, 2 and 3) and human respiratory syncytial virus (subgroups A and B) vaccines using bovine parainfluenza virus 3 as a vector.

在临床试验中显示牛parainfluenza 3型病毒（BPIV3）在给小婴儿和儿童时是安全的，并减弱了，不会引起儿童的下呼吸道疾病。 BPIV3在儿童复制后遗传稳定。这三个特征为将BPIV3用作提供外抗原的有效矢量车辆提供了基础。最近，在Aviron上设计了BPIV3的传染性cDNA，该cn允许通过反向遗传学分离重组病毒。该阶段I SBIR建议将通过将人副副磷氟烷病毒的表面糖蛋白引入L，2和3（HPIV1、2、3）和人呼吸伴合依症病毒（HRSV）（hrsv）（亚组A和B）（亚组A和B）（亚组A和B）中，以证明这种方法的可行性。 HPIV和HRSV。是婴儿，儿童和免疫功能低下或老年人的上呼吸道疾病的原因，不仅导致大量住院，而且导致发病率。目前尚无疫苗用于PIV或RSV相关疾病，迄今为止，亚基方法已经失败。 II期SBIR赠款将用于在亚人类灵长类动物模型中完成临床前测试，并启动人类临床试验。拟议的商业应用：这些研究的最终产物是使用牛parainfluenza病毒3作为载体的载体，是人类副帕鲁氏病毒（L，2型和3型）和人呼吸道合胞病毒（亚组A和B）疫苗。